Download PDF
Aktuelle Dermatologie 2019; 45(01/02): 72-85
DOI: 10.1055/a-0601-9347
CME-Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Erworbene retikuläre Pigmentdermatosen

Acquired Reticular Pigmented Dermatoses
C. S. L. Müller
,
T. Vogt
Subject Editor: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. med. Cornelia S. L. Müller, Homburg/Saar.
Further Information

Publication History

Publication Date:
12 February 2019 (online)

Also available at
   Permissions and Reprints

Die klinischen Differenzialdiagnosen erworbener Hyperpigmentierungen der Haut sind vielfältig. Seltenheit und unscharfe Abgrenzungen zwischen den verschiedenen Entitäten auf der einen und auch vermeintliche Unbedeutsamkeit und Harmlosigkeit der Dermatosen auf der anderen Seite verzögern oft eine zügige Diagnose im klinischen Alltag. In der vorliegenden Arbeit sollen die wichtigsten klinischen Differenzialdiagnosen erläutert werden.

Abstract

Clinical differential diagnoses of acquired hyperpigmentation of the skin are manifold. The rarity and fuzzy demarcation between various entities on the one hand and the alleged insignificance and harmlessness of the dermatoses on the other hand often delay a rapid diagnosis in everyday clinical practice. In the present work the most important clinical differential diagnoses are reviewed. Acquired reticular pigment dermatoses (RPD) of the skin sui generis include Dowling-Degos disease (DDD), Galli-Galli disease (GGD). Further diseases rarely found in Europe are Kitamura disease (RKD), reticular acropigmentation Dohi (RAD) and Haber syndrome (HS). Other acquired more frequent hyperpigmentation of the skin, which may also have a reticular pattern, include acanthosis nigricans, papillomatosis confluens et reticularis Gougerot carteaud, diabetic dermatopathy, and postinflammatory hyperpigmentation. Some of these diseases are particularly indicative of endocrinopathies. In particular, childhood acanthosis nigricans is of great importance in diabetes mellitus screening. Histopathological examination with the clinical problem of acquired hyperpigmentation can be difficult and requires close clinical-pathological correlation.

Kernaussagen

  • Diverse entzündliche und infektiöse Erkrankungen führen zu teils auch retikulären Hyperpigmentierungen an der Haut.

  • Von den retikulären Pigmentdermatosen sui generis kommen der Morbus Dowling-Degos und der Morbus Galli-Galli am häufigsten vor.

  • Differenzialdiagnostisch müssen erregerbedingte Dermatosen, wie die Pityriasis versicolor, von postinflammatorischen Hyperpigmentierungen abgegrenzt werden, nach Akne, Ekzem, Lichen planus u. a. m.

  • Die erworbenen Hyperpigmentierungen der großen Körperfalten, Akanthosis nigricans und Papillomatosis confluens et reticularis Gougerot Carteaud, sind häufig mit Stoffwechselerkrankungen assoziiert und können u. a. eine (latente/subklinische) diabetische Stoffwechsellage anzeigen.

  • Die Papillomatosis confluens et reticularis Gougerot Carteaud scheint durch eine Besiedelung mit dem Bakterium Dietzia papillomatosis assoziiert zu sein und wird mit Minozyklin oft erfolgreich behandelt.

  • Biopsien dienen der Ausschlussidagnostik und sollten zusammen mit ausführlichem klinischem Befund, Anamnesedaten und am besten einer Fotodokumentation eingesendet werden.

Schlüsselwörter

erworbene Hyperpigmentierungen - Hypopigmentierungen - Pilzinfektionen - Genodermatose - Histopathologie

Keywords

acquired hyperpigmentation - hypopigmentation - mycotic infectious diseases - histopathology - genodermatoses
 

  • Literatur

  • 1 Müller CS, Pföhler C, Tilgen W. Changing a concept – controversy on the confusing spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol 2009; 36: 44-48
    CrossrefPubMedGoogle Scholar
  • 2 Müller CS, Tremezaygues L, Pföhler C. et al. The spectrum of reticulate pigment disorders of the skin revisited. Eur J Dermatol 2012; 22: 596-604
    PubMedGoogle Scholar
  • 3 Hanneken S, Rütten A, Eigelshoven S. et al. [Galli-Galli disease. Clinical and histopathological investigation using a case series of 18 patients]. Hautarzt 2011; 62: 842-851
    CrossrefPubMedGoogle Scholar
  • 4 Hanneken S, Rütten A, Pasternack SM. et al. Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. Br J Dermatol 2010; 163: 197-200
    CrossrefPubMedGoogle Scholar
  • 5 Cabral AR, Santiago F, Reis JP. Coexistence of reticulate acropigmentation of Kitamura and Dowling-Degos disease. Dermatol Reports 2011; 3: e33
    CrossrefPubMedGoogle Scholar
  • 6 Rathoriya SG, Soni SS, Asati D. Dowling-Degos disease with reticulate acropigmentation of Kitamura: Extended spectrum of a single entity. Indian Dermatol Online J 2016; 7: 32-35
    CrossrefPubMedGoogle Scholar
  • 7 Thami GP, Jaswal R, Kanwar AJ. et al. Overlap of reticulate acropigmentation of Kitamura, acropigmentation of Dohi and Dowling-Degos disease in four generations. Dermatology 1998; 196: 350-351
    CrossrefPubMedGoogle Scholar
  • 8 Vasudevan B, Verma R, Badwal S. et al. A case of reticulate acropigmentation of kitamura: dowling degos disease overlap with unusual clinical manifestations. Indian J Dermatol 2014; 59: 290-292
    CrossrefPubMedGoogle Scholar
  • 9 Dowling GB, Freudenthal W. Acanthosis Nigricans. Proc R Soc Med 1938; 31: 1147-1150
    PubMedGoogle Scholar
  • 10 Bardach H, Gebhart W, Luger T. [Genodermatosis in a pair of brothers: Dowling-Degos, Grover, Darier, Hailey-Hailey or Galli-Galli disease?]. Hautarzt 1982; 33: 378-383
    PubMedGoogle Scholar
  • 11 El Shabrawi-Caelen L, Rütten A, Kerl H. The expanding spectrum of Galli-Galli disease. J Am Acad Dermatol 2007; 56 (Suppl. 05) S86-91
    CrossrefPubMedGoogle Scholar
  • 12 Zhang J, Li M, Yao Z. Updated review of genetic reticulate pigmentary disorders. Br J Dermatol 2017; 177: 945-959
    CrossrefPubMedGoogle Scholar
  • 13 Gupta A, Huilgol SC. Successful treatment of Dowling-Degos disease using intense pulsed light. Australas J Dermatol 2015; 56: e63-65
    CrossrefPubMedGoogle Scholar
  • 14 Khaddar RK, Mahjoub WK, Zaraa I. et al. [Extensive Dowling-Degos disease following long term PUVA therapy]. Ann Dermatol Venereol 2012; 139: 54-57
    CrossrefPubMedGoogle Scholar
  • 15 Kitamura K, Akamatsu S. Pigmentary disorders. Rinsho No Hifu Hitsunyo 1943; 8: 201-204
    PubMedGoogle Scholar
  • 16 Okamura K, Abe Y, Araki Y. et al. Behavior of melanocytes and keratinocytes in reticulate acropigmentation of Kitamura. Pigment Cell Melanoma Res 2016; 29: 243-246
    CrossrefPubMedGoogle Scholar
  • 17 Toyama I. [An unknown disorder of hyperpigmentation]. Jpn J Dermatol Urol 1910; 10: 644 (In Japanese)
    PubMedGoogle Scholar
  • 18 Toyama I. [Dyschromatosis symmetrica hereditaria]. Jpn J Dermatol Urol 1929; 27: 95-96 (In Japanese)
    PubMedGoogle Scholar
  • 19 Liu Q, Liu W, Jiang L. et al. Novel mutations of the RNA-specific adenosine deaminase gene (DSRAD) in Chinese families with dyschromatosis symmetrica hereditaria. J Invest Dermatol 2004; 122: 896-899
    CrossrefPubMedGoogle Scholar
  • 20 Suzuki N, Suzuki T, Inagaki K. et al. Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. J Invest Dermatol 2005; 124: 1186-1192
    CrossrefPubMedGoogle Scholar
  • 21 Kondo T, Suzuki T, Mitsuhashi Y. et al. Six novel mutations of the ADAR1 gene in patients with dyschromatosis symmetrica hereditaria: histological observation and comparison of genotypes and clinical phenotypes. J Dermatol 2008; 35: 395-406
    CrossrefPubMedGoogle Scholar
  • 22 Murata I, Hozumi Y, Kawaguchi M. et al. Four novel mutations of the ADAR1 gene in dyschromatosis symmetrica hereditaria. J Dermatol Sci 2009; 53: 76-77
    CrossrefPubMedGoogle Scholar
  • 23 Kondo T, Suzuki T, Ito S. et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J Dermatol 2008; 35: 662-666
    CrossrefPubMedGoogle Scholar
  • 24 Sanderson KV, Wilson HT. Haber’s Syndrome. Familial Rosacea-Like Eruption with Intraepidermal Epithelioma. Br J Dermatol 1965; 77: 1-8
    CrossrefPubMedGoogle Scholar
  • 25 Pollitzer S. Acanthosis nigricans: a symptom of a disorder of the abdominal sympathetic. J Am Med Assoc 1909; 53: 1369-1373
    PubMedGoogle Scholar
  • 26 Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994; 31: 1-19 quiz 20 – 22
    CrossrefPubMedGoogle Scholar
  • 27 Kutlubay Z, Engin B, Bairamov O. et al. Acanthosis nigricans: A fold (intertriginous) dermatosis. Clin Dermatol 2015; 33: 466-470
    CrossrefPubMedGoogle Scholar
  • 28 Bhagyanathan M, Dhayanithy D, Parambath VA. et al. Acanthosis nigricans: A screening test for insulin resistance – An important risk factor for diabetes mellitus type-2. J Family Med Prim Care 2017; 6: 43-46
    CrossrefPubMedGoogle Scholar
  • 29 Aswani R, Lochow A, Dementieva Y. et al. Acanthosis nigricans as a clinical marker to detect insulin resistance in Caucasian children from West Virginia. Clin Pediatr (Phila) 2011; 50: 1057-1061
    CrossrefPubMedGoogle Scholar
  • 30 Hida Y, Kubo Y, Nishio Y. et al. Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. Acta Derm Venereol 2009; 89: 435-437
    PubMedGoogle Scholar
  • 31 Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007; 57: 502-508
    CrossrefPubMedGoogle Scholar
  • 32 Fukuchi K, Tatsuno K, Matsushita K. et al. Familial acanthosis nigricans with p. K650T FGFR3 mutation. J Dermatol 2018; 45: 207-210
    CrossrefPubMedGoogle Scholar
  • 33 Hafner C, Hartmann A, van Oers JM. et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod Pathol 2007; 20: 895-903
    PubMedGoogle Scholar
  • 34 Ng HY. Acanthosis nigricans in obese adolescents: prevalence, impact, and management challenges. Adolesc Health Med Ther 2017; 8: 1-10
    PubMedGoogle Scholar
  • 35 Ehsani A, Noormohammadpour P, Goodarzi A. et al. Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: A case series of patients in a before-after trial. Caspian J Intern Med 2016; 7: 290-293
    PubMedGoogle Scholar
  • 36 Campos MA, Varela P, Baptista A. et al. Unilateral nevoid acanthosis nigricans treated with CO2 laser. BMJ Case Rep 2016; pii: bcr2016216073. DOI: 10.1136/bcr-2016-216073.
    CrossrefPubMedGoogle Scholar
  • 37 Swineford SL, Drucker CR. Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids. J Drugs Dermatol 2010; 9: 1151-1153
    PubMedGoogle Scholar
  • 38 Kuroki R, Sadamoto Y, Imamura M. et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999; 198: 164-166
    CrossrefPubMedGoogle Scholar
  • 39 Elmer KB, George RM. HAIR-AN syndrome: a multisystem challenge. Am Fam Physician 2001; 63: 2385-2390
    PubMedGoogle Scholar
  • 40 Melibary YT. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). Dermatol Reports 2018; 10: 7546
    PubMedGoogle Scholar
  • 41 Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res 2000; 54: 251-258
    CrossrefPubMedGoogle Scholar
  • 42 Dalamaga M, Papadavid E, Basios G. et al. Ovarian SAHA syndrome is associated with a more insulin-resistant profile and represents an independent risk factor for glucose abnormalities in women with polycystic ovary syndrome: a prospective controlled study. J Am Acad Dermatol 2013; 69: 922-930
    CrossrefPubMedGoogle Scholar
  • 43 Gougerot H, Carteaud A. La papillomatose papuleuse confluente et réticulée. Ann Dermatol Syphiligr (Paris) 1947; 7: 325-329
    PubMedGoogle Scholar
  • 44 Lim JH, Tey HL, Chong WS. Confluent and reticulated papillomatosis: diagnostic and treatment challenges. Clin Cosmet Investig Dermatol 2016; 9: 217-223
    CrossrefPubMedGoogle Scholar
  • 45 Park YJ, Kang HY, Lee ES. et al. Differentiating confluent and reticulated papillomatosis from acanthosis nigricans. J Cutan Pathol 2015; 42: 944-952
    CrossrefPubMedGoogle Scholar
  • 46 Le C, Bedocs PM. Confluent And Reticulated Papillomatosis. StatPearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 –. 2018 Oct 27.
    PubMedGoogle Scholar
  • 47 Jo S, Park HS, Cho S. et al. Updated diagnosis criteria for confluent and reticulated papillomatosis: a case report. Ann Dermatol 2014; 26: 409-410
    CrossrefPubMedGoogle Scholar
  • 48 Duncan WC, Tschen JA, Knox JM. Terra firma-forme dermatosis. Arch Dermatol 1987; 123: 567-569
    CrossrefPubMedGoogle Scholar
  • 49 Seegräber M, Aukstikalnyte A, Herzinger T. et al. [Terra firma-forme dermatosis]. Hautarzt 2018; 69 (Suppl. 01) 9-10
    CrossrefPubMedGoogle Scholar
  • 50 Demirci GT, Mansur AT, Demiralay E. Terra Firma-Forme Dermatosis Misdiagnosed as Nevoid Acanthosis Nigricans. Am J Dermatopathol 2017; 39: 782-784
    CrossrefPubMedGoogle Scholar
  • 51 Neri I, Savoia F, Tengattini V. et al. Terra firma-forme dermatosis is underestimated in children and is associated with atopic dermatitis. J Eur Acad Dermatol Venereol 2018; 32: e421-e422
    CrossrefPubMedGoogle Scholar
  • 52 Karray M, McKinney WP. Tinea, Versicolor. StatPearls. [Internet] Treasure Island (FL): StatPearls Publishing; 2018 –. 2018 Oct 27.
    PubMedGoogle Scholar
  • 53 Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: Part II. Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation. Am Fam Physician 2003; 68: 1963-1968
    PubMedGoogle Scholar
  • 54 Clerc OF, Kaufmann BP, Possner M. et al. Long-term prognostic performance of low-dose coronary computed tomography angiography with prospective electrocardiogram triggering. Eur Radiol 2017; 27: 4650-4660
    CrossrefPubMedGoogle Scholar
  • 55 Savory SA, Agim NG, Mao R. et al. Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris. J Am Acad Dermatol 2014; 70: 108-114
    CrossrefPubMedGoogle Scholar
  • 56 Tomita Y, Maeda K, Tagami H. Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation. Pigment Cell Res 1992; 5: 357-361
    CrossrefPubMedGoogle Scholar
  • 57 Park JY, Park JH, Kim SJ. et al. Two histopathological patterns of postinflammatory hyperpigmentation: epidermal and dermal. J Cutan Pathol 2017; 44: 118-124
    CrossrefPubMedGoogle Scholar
  • 58 Kaufman BP, Aman T, Alexis AF. Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment. Am J Clin Dermatol 2018; 19: 489-503
    CrossrefPubMedGoogle Scholar
  • 59 Maymone MBC, Neamah HH, Wirya SA. et al. Sun-protective behaviors in patients with cutaneous hyperpigmentation: A cross-sectional study. J Am Acad Dermatol 2017; 76: 841-846.e2
    CrossrefPubMedGoogle Scholar
  • 60 Alexis AF, Blackcloud P. Natural ingredients for darker skin types: growing options for hyperpigmentation. J Drugs Dermatol 2013; 12 (Suppl. 09) s123-s127
    PubMedGoogle Scholar
  • 61 Nestor M, Bucay V, Callender V. et al. Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders. J Clin Aesthet Dermatol 2014; 7: 13-17
    PubMedGoogle Scholar
  • 62 Kerl H, Cerroni L. “Standard of reasonable care” in dermatopathology. J Dtsch Dermatol Ges 2011; 9: 721-722
    PubMedGoogle Scholar